

UCSF

UC San Francisco Previously Published Works

Title

Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells.

Permalink

<https://escholarship.org/uc/item/4gj9v1sx>

Journal

Cell Stem Cell, 11(1)

Authors

Tomoda, Kiichiro
Takahashi, Kazutoshi
Leung, Karen
[et al.](#)

Publication Date

2012-07-06

DOI

10.1016/j.stem.2012.05.019

Peer reviewed



Published in final edited form as:

Cell Stem Cell. 2012 July 6; 11(1): 91–99. doi:10.1016/j.stem.2012.05.019.

Derivation Conditions Determine X-Reactivation Status in Female Human Induced Pluripotent Stem Cells

Kiichiro Tomoda¹, Kazutoshi Takahashi², Karen Leung⁴, Aki Okada², Megumi Narita², N. Alice Yamada³, Kirsten E. Eilertson¹, Peter Tsang³, Shiro Baba¹, Mark P. White¹, Salma Sami¹, Deepak Srivastava¹, Bruce R. Conklin¹, Barbara Panning^{4,5}, and Shinya Yamanaka^{1,2,5}

¹Gladstone Institute of Cardiovascular Disease, University of California San Francisco, San Francisco, CA 94158, USA

²Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan

³Agilent Laboratories, Agilent Technologies, Santa Clara, CA 95051, USA

⁴Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA

SUMMARY

Female human induced pluripotent stem cell (hiPSC) lines exhibit variability in X-inactivation status. The majority of hiPSC lines maintain one transcriptionally active X (Xa) and one inactive X (Xi) chromosome from donor cells. However, at low frequency, hiPSC lines with two Xas are produced, suggesting that epigenetic alterations of the Xi occur sporadically during reprogramming. We show here that X-inactivation status in female hiPSC lines depends on derivation conditions. hiPSC lines generated by the Kyoto method (retroviral or episomal reprogramming), which uses leukemia inhibitory factor (LIF)-expressing SNL feeders, frequently had two Xas. Early passage Xa/Xi hiPSC lines generated on non-SNL feeders were converted into Xa/Xa hiPSC lines after several passages on SNL feeders, and supplementation with recombinant LIF caused reactivation of some of X-linked genes. Thus, feeders are a significant factor affecting X-inactivation status. The efficient production of Xa/Xa hiPSC lines provides unprecedented opportunities to understand human X-reactivation and inactivation.

INTRODUCTION

Female human induced pluripotent stem cell (hiPSC) and human embryonic stem cell (hESC) lines with two active X chromosomes (Xa) occur infrequently, and Xa/Xa hESC lines often become Xa/Xi (Bruck and Benvenisty, 2011; Cheung et al., 2011; Fan and Tran, 2011; Hanna et al., 2010; Hoffman et al., 2005; Lagarkova et al., 2010; Lengner et al., 2010; Marchetto et al., 2010; Pomp et al., 2011; Shen et al., 2008; Silva et al., 2008; Tchieu et al., 2010; Teichroeb et al., 2011). Some Xa/Xa hESC lines do not exhibit X-inactivation upon differentiation (Hoffman et al., 2005). The reasons for this variability are not fully understood, but derivation and culture conditions affect epigenetic features of X

© 2012 Il Press. All rights reserved

⁵Correspondence: barbara.panning@ucsf.edu; shinya.yamanaka@gladstone.ucsf.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

chromosomes (Hanna et al., 2010; Lengner et al., 2010; Pomp et al., 2011; Ware et al., 2009).

This study investigated the X-inactivation status of hiPSCs derived by the Kyoto method, which uses SNL feeder cells that produce high level of leukemia inhibitory factor (LIF) (McMahon and Bradley, 1990; Nakagawa et al., 2008; Takahashi et al., 2007). We report here that the Xi of donor fibroblasts was frequently reactivated in hiPSC lines generated on SNLs. Early passage hiPSC lines were Xa/Xi and converted into Xa/Xa lines upon continued passage on SNL but not non-SNL feeders. Lines cultured on non-SNL feeders supplemented with LIF had features of X-reactivation. These data indicate that feeder cells significantly affect X-inactivation status and that LIF contributes to reactivation. Reliably generating hiPSCs with the desired Xa/Xi or Xa/Xa pattern is useful in disease modeling and clinical applications.

RESULTS

X-Linked Genes Are Highly Expressed in Female hiPSC Lines

We used microarrays to examine X-linked gene expression in hiPSC lines derived from differentiated H9 ESCs (H9-reporter) (Figures 1A and B, S1A–I and Table S1) or human fibroblasts (hFibs) (Figures 1D and E, S1J–Q and Table S1). Approximately 40% of X-linked genes were expressed at >1.5-fold higher levels in female hiPSC lines than in Xa/Xi or XY hESC lines (Figure 1C). Plotting the expression ratios of female hiPSCs and hESCs onto the human genome revealed that the X was the only chromosome with chromosome-wide upregulation in hiPSCs (Figure 1F). Thus, X-linked genes are specifically upregulated in female hiPSCs derived from differentiated hESCs or hFibs, suggesting X-reactivation in female hiPSCs.

Two Xs Are Active in Female hiPSCs

We next examined expression of two X-linked genes, *PGKI* and *XIST*, by fluorescent *in situ* hybridization (FISH). We found >60% of hiPSCs had two sites of nuclear transcript accumulation for *PGKI*, in contrast to a Xa/Xi hESC line, which had only one site in ~60% of cells (Figure 2A and B). *XIST* RNA coating and high expression were detected in Xa/Xi hESCs, but not in hiPSCs (Figure 2A and C). In addition, a majority of hiPSCs exhibited RNA polymerase II (polII) staining on both Xs, while hESCs exhibited staining on one X (Figure 2D), indicating that these hiPSC lines have two Xs.

By single nucleotide polymorphism (SNP) sequencing, the X-linked gene, *WDR44*, was expressed at a higher level in the hiPSCs derived from differentiated H9-reporter cells (H9r iPSCs) than in H9-reporter ESCs (Figure 2E, left) and detected from both alleles only in H9r iPSCs (Figure 2E, right). Bisulfite sequencing of the *WDR44* promoter showed hESCs had a mixed methylation pattern characteristic of Xa/Xi cell lines (Heard and Disteché, 2006; Shen et al., 2008), while hiPSCs were hypomethylated (Figure 2F).

Finally, we used X to autosome expression ratios (X/A ratios): Xa/Xi cell lines have lower X/A ratios than Xa/Xa cell lines (Bruck and Benvenisty, 2011; Lin et al., 2007; Nguyen and Disteché, 2006). X/A ratios derived from deposited microarray data sets from hiPSC and hESC lines in which X-inactivation status is already characterized (Hanna et al., 2010; Lengner et al., 2010; Tchieu et al., 2010) were well correlated with X-inactivation status (Figure 2G, left three lanes). We found that X/A ratios from our female hiPSCs were comparable to reported Xa/Xa cells. These results confirmed X-reactivation in hiPSCs and indicate X/A ratios provide a useful method of identifying potential Xa/Xa hiPSC lines.

One X Is Inactivated upon Differentiation of Female hiPSCs

We analyzed a pure population of cells differentiated into endothelial cells. Xa/Xa hiPSC-derived endothelial cells exhibited low X/A ratios, comparable to primary endothelial cells and those differentiated from male or Xa/Xi hESCs (Figure 2H). XIST RNA was not detected, while only a single site of nascent *PGK1* transcript accumulation was detected in > 60% of Xa/Xa-derived endothelial cells (Figure 2I and J). These results indicate that one X is silenced after differentiation of Xa/Xa hiPSCs.

Prolonged Culture Promotes X-Reactivation in hiPSCs Derived and Propagated on SNL Feeders

We analyzed X-inactivation status in more hFib-derived hiPSC lines generated on SNLs by three- or four-factor viral reprogramming or integration-free episomal vector reprogramming (Okita et al., 2011) (Table S1). At early passage (passage (p)5), X/A ratios of all lines analyzed were consistent with reported Xa/Xi lines (Figure 3A, at p5 on SNLs). At late passage (>p15), 20 of 23 lines exhibited high X/A ratios (X/A > 0.3), comparable to those reported for Xa/Xa cells (Figure 3A, at > p15 on SNLs). Two cell lines at > p15 were further analyzed for X-inactivation by FISH, and the majority of cells showed two sites of nuclear transcript accumulation for *PGK1* and no XIST RNA accumulation, indicating these lines are also Xa/Xa (Figure 3B). Further, Xa/Xa status was maintained with continued passage (Table S1). These results suggest our method frequently produces stable Xa/Xa hiPSCs.

By microarray analysis, *XIST* expression in all female hiPSCs on SNLs at early passage was similar to the donor Xa/Xi hFibs. At late passage, *XIST* was down regulated. We confirmed these findings by quantitative RT-PCR (Figure 3C). Also, SNP sequencing revealed that two X-linked genes (*TSPAN6* and *FRMPD4*) are mono-allelically expressed at early passage but bi-allelically expressed at late passage of hiPSCs on SNLs (Figure 3D). These SNP sequencing results, together with the X/A ratios and *XIST* expression, indicate that the Xi is silent at early passage but is reactivated with continued propagation, concomitant with down-regulation of *XIST*.

Feeder Cells Affect X-inactivation Status in Female hiPSCs

Most female hiPSC lines reprogrammed with our protocol were Xa/Xa, but others laboratories reported Xa/Xi hiPSC lines derived using with the same reprogramming factors (Hanna et al., 2010; Pomp et al., 2011; Tchieu et al., 2010). A notable difference between protocols is the type of feeder cells employed. We used SNLs, which are immortalized mouse embryonic fibroblasts that express a LIF transgene (Takahashi et al., 2007), while other laboratories predominantly use mouse primary embryonic fibroblasts (MEFs) (Hanna et al., 2010; Pomp et al., 2011; Tchieu et al., 2010). Thus, we analyzed female hiPSC lines generated on non-SNLs, hFibs (Takahashi et al., 2009) or MEFs (Tchieu et al., 2010) (Table S1). None of the hiPSC lines derived on non-SNLs (0/12) had high X/A ratios (> 0.3) at > p15 (Figure 3A, at > p15 on non-SNLs). Three lines were analyzed by FISH, and the majority of cells had only one site of *PGK1* accumulation with or without XIST RNA coating (Figure 3E and F). Therefore, hiPSCs generated on non-SNLs retain one Xi as reported (Pomp et al., 2011; Tchieu et al., 2010).

SNLs Have a Role in X-Reactivation in Female hiPSCs

Since LIF is secreted by SNLs, we examined its role on X chromosome-wide gene expression by our protocol. Female hiPSC lines were initially generated on non-SNLs (hFibs or MEFs) and transferred to SNLs or non-SNLs plus recombinant (r)LIF (Figure 4A). For hiPSCs generated on hFibs, transfer occurred at p9. For hiPSCs generated on MEFs, transfer occurred at p1, when hiPSC colonies were initially picked. Female hiPSC lines transferred

to SNLs had increased X/A ratios, concomitant with down regulated *XIST* and up-regulated X-linked genes. None of the sister lines continually cultured on non-SNLs had substantially increased X/A ratios, suggesting they remain Xa/Xi (Figures 4B–D and S3A–B). The two hiPSC lines generated on MEFs and transferred to SNLs had X/A ratios similar to those generated and cultured on SNLs and bi-allelic expression of *TSPAN6* and *FRMPD4* (Figure 4C and E). While the hiPSC lines generated on hFibs and transferred to SNLs had increased X/A ratios, the ratios were lower than when hiPSCs were derived exclusively on SNLs, which may be a consequence of initial reprogramming on hFibs and/or the later transfer to SNLs (Figure 4B). In support of the timing of transfer affecting X-inactivation status, one of four hiPSC lines generated on MEFs and transferred to SNLs at p4 or p7 had features of X-reactivation (Figure S3D and E). Thus, culture on SNLs can convert early passage Xa/Xi hiPSCs generated and cultured on non-SNLs into Xa/Xa hiPSCs.

Two of four hiPSC lines generated on non-SNLs and transferred to non-SNLs plus rLIF had increased X/A ratios, concomitant with down regulation of *XIST* and up-regulation of X-linked genes (Figures 4B, C, F and S3A and B). In a line derived on hFibs and transferred to hFibs plus rLIF at p9, the X/A ratio was comparable to that of the sister line after transfer to SNLs (Figure 4B). The line derived on MEFs and transferred to MEFs plus rLIF at p1 had a lower X/A ratio than its sister line that was transferred to SNLs at p1. While transfer to SNLs elicited bi-allelic expression of *FRMPD4* and *TSPAN6* (Figure 4E), transfer to MEFs plus rLIF caused bi-allelic expression of *PGK1* (Figure 4G) and *FRMPD4* but not *TSPAN6* (Figures 4H), suggesting that rLIF promotes reactivation of a subset of X-linked genes.

Next we asked if the intermediate X/A ratio in hiPSCs cultured on non-SNLs plus rLIF reflected intermediate X-linked gene expression across the entire chromosome. We plotted expression levels of genes across the X from hiPSCs transferred to non-SNLs plus rLIF or SNLs, normalized to the expression of hiPSCs maintained on non-SNLs for the same number of passages (Figure 4I for MEF hiPSCs and S3C for hFib hiPSCs). There was variability across the X (Figure 4I). Some regions were more similar between the MEF plus rLIF hiPSCs and MEF hiPSCs and other regions were more similar between the MEF plus rLIF hiPSCs and SNL hiPSCs, suggesting that rLIF promotes full reactivation of a subset of X-linked genes. On the remainder of the X the MEF plus rLIF hiPSCs had expression intermediate to MEF hiPSCs and SNL hiPSCs, which may reflect up regulation of the Xa or X-reactivation upon addition of rLIF. *FRMPD4* lies in a region of intermediate expression, suggesting that, while there is bi-allelic expression, the reactivated genes may not be expressed as highly in MEF plus rLIF hiPSCs than in SNL hiPSCs. Our results indicate reprogramming with SNL feeders promotes robust X-reactivation, and LIF may contribute to this epigenetic alteration of the Xi.

DISCUSSION

In this study, we showed that female hiPSCs derived by the Kyoto method, using retroviral or episomal vectors, frequently have two Xas. In female hiPSCs derived from hFibs, the Xi remained silent at early passage, but reactivated later, concomitant with down-regulation of *XIST*. Since episomal reprogramming (Okita et al., 2011) supported X-reactivation, neither viral integration nor continued expression of exogenous factors is necessary for this process. Xa/Xa hiPSCs were poised for X-inactivation upon differentiation. The high frequency X-reactivation and stable Xa/Xa status in hiPSCs derived with the Kyoto method (17/20 retroviral, 3/3 episomal) contrasts the sporadic or lack of X-reactivation of other methods (Cheung et al., 2011; Hanna et al., 2010; Kim et al., 2011; Lagarkova et al., 2010; Marchetto et al., 2010; Mekhoubad et al., 2012; Pomp et al., 2011; Tchieu et al., 2010). Thus, this method provides an unprecedented tool to understand epigenetic regulation of X chromosomes in human cells.

SNL Feeders Are Important for X-Reactivation

The Kyoto method uses SNL feeders to derive and maintain hiPSCs. When MEFs or hFibs feeders were used, we did not observe frequent production of Xa/Xa hiPSC lines. However, early passage Xa/Xi hiPSCs generated and cultured on non-SNLs could be converted into Xa/Xa after several passages on SNLs, implicating SNLs in X-reactivation.

SNLs supported production of hiPSCs with two Xas, suggesting a role for LIF in X-reactivation. Indeed, transfer into rLIF-containing medium caused up-regulation of X-linked genes and increased X/A ratios in two of four hiPSC lines initially generated on non-SNLs. While transfer to rLIF promoted up-regulation of X-linked genes, not all genes were up-regulated to the same extent as on SNLs, and some were not up-regulated at all. Also, not all genes assayed exhibited bi-allelic gene expression in hiPSCs cultured with rLIF. Thus, culture with rLIF does not have the same chromosome-wide effects that are seen with culture on SNLs. Thus, SNLs may have activities in addition to LIF that enable frequent and chromosome-wide X-reactivation. One possible activity is glycosylation of LIF: glycosylated LIF may have different roles from non-glycosylated LIF (Blanchard et al., 1998), and rLIF is not glycosylated. Identification of such activities, including LIF glycosylation, is an important future task.

Overexpression of OCT3/4, KLF2 and KLF4 in conjunction with MAPKK and GSK3b inhibitors and rLIF stochastically converts Xa/Xi hiPSCs into Xa/Xa hiPSCs (Hanna et al., 2010). In this study, we showed that expression of exogenous OCT3/4 and KLF4 during culture is not required for reactivation. While our results suggest that LIF contributes to SNL-mediated X-reactivation, the effect of SNLs on MAPK and GSK3b pathways should also be investigated.

The timing of transfer to SNLs may affect X-inactivation status, as transfer of initial hiPSC colonies directly onto SNLs resulted in X-reactivation. In contrast, transfer of four Xa/Xi hiPSCs to SNLs at p15 or later did not promote X-reactivation (data not shown). Since the reprogramming process continues during expansion of iPSC clones (Polo et al., 2010), perhaps early exposure to SNLs during this dynamic stage of reprogramming impacts X-linked gene expression at later passage. Epigenetic alterations acquired during culture without SNLs may render the Xi less responsive to the signals that trigger reactivation.

Implication for Medical Applications

A small number of hiPSC lines fail to reactivate the Xi even on SNL feeders. While these Xa/Xi lines are indistinguishable from Xa/Xa lines in differentiation ability and global expression patterns of autosomal genes, these Xa/Xi lines might not be fully reprogrammed. In mouse, there is a relationship between X-reactivation and the “naive” pluripotent state, in which pluripotent cells efficiently contribute to chimeric embryos (Fan and Tran, 2011; Nichols and Smith, 2009; Payer et al., 2011). If the developmental potential of Xa/Xa hiPSCs is also greater, the insights obtained from the Kyoto method may be advantageous for reliable production of quality hiPSCs for future medical applications. However, when treating X-linked human monogenic diseases, such as Rett syndrome, Xa/Xi hiPSCs in which the Xi carries the mutation would be a more attractive source of material for cell-replacement therapies (Tchieu et al., 2010).

A Model System for Study of X-Inactivation and X-Reactivation in Humans

The efficient X-reactivation in our hiPSC lines is a useful tool for elucidating mechanisms of X-reactivation in human cells. Furthermore, a reliable source of Xa/Xa hiPSC lines poised for X-inactivation provides tools to study this process. X-reactivation and X-inactivation have mainly been examined in mouse systems. However, the mechanisms in

human may differ from those in mouse (Maherali et al., 2007; Okamoto et al., 2011; Tchieu et al., 2010; van den Berg et al., 2009). The difficulty in obtaining human embryos and the unstable X-inactivation status in hESCs make it extremely difficult to study X-inactivation in humans (Okamoto et al., 2011; van den Berg et al., 2009). Our hiPSCs may overcome these challenges.

The role of *XIST* during X-inactivation is not clear in human cells. Our hiPSC lines exhibited X-inactivation upon differentiation. However, there was no detectable *XIST* expression in the resulting purified endothelial cells. While it is unusual for differentiated cells not to express *XIST*, this non-coding RNA is not necessary for maintenance of X-inactivation (Brown and Willard, 1994) and can be epigenetically silenced in cultured cells, including hESCs (Shen et al., 2008; Silva et al., 2008; Tchieu et al., 2010). Further analyses of our hiPSCs could provide new insights into regulation of *XIST* expression and X-inactivation in humans.

EXPERIMENTAL PROCEDURES

EXTENDED EXPERIMENTAL PROCEDURES is described in the Supplemental Information.

hiPSC Generation and Cell Culture

All hiPSC lines were generated by established protocols (<http://www.cira.kyotou.ac.jp/e/research/protocol.html>). All hESC lines were obtained from the National Stem Cell Bank (WiCell). hiPSC and hESC lines (Table S1) were maintained using standard protocols (Takahashi et al., 2007), with the exception that human insulin-like growth factor II (Chemicon; 33 ng/ml) was added into the ES medium at Gladstone. Recombinant human LIF (Millipore; 10 ng/ml) was added into the medium as indicated. All karyotyping was performed at StemCell Technology, US, or the Nihon Gene Research Laboratories, Japan. In all instances, passage 1 (p1) refers to when colonies are initially picked. SNL feeder cells are available at Health Protection Agency Culture Collection (http://www.hpacultures.org.uk/products/celllines/generalcell/detail.jsp?refId=07032801&collection=ecacc_gc).

Microarray and Bioinformatics

Microarray (Whole Human Genome Microarray 4 × 44K or G3, Agilent) analyses were performed as described (Takahashi et al., 2007). All gene expression values were normalized by the 75% percentile shift method. All (Figure 1B and E) or probes that were used for calculation of X/A ratios (Figure S3A and B) were used for the heat maps. In Figures 1E, 4I and S3C, IGV software (Broad Institute) was used. For Figure 1E, the expression ratios were calculated with averaged data from female hESC (ESI03, H7, H9 and H9-reporter) and hiPSC (K-3F-1, K-3F-2 and 3S-5F-4) lines. For Figures 4I and S3C, the expression ratios were calculated using selected data that were also used for Figure 4B or C. The microarray data for the deposited Xa/Xi and Xa/Xa lines used were downloaded from NCBI GEO (GEO number: GSE21222 and GSE22246). We have deposited the microarray data of hiPSC and hESC lines to GEO DataSets with the accession number GSE34527.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank members of Yamanaka laboratory for useful discussions, Tim Rand for plotting the results of bisulfite sequencing and X/A ratios, Kenta Nakamura for hiPSC differentiation and useful discussions, Laura Mitic for maintaining the confocal microscope, Lei Lue for the endothelial cell differentiation, Michiyo Koyanagi for microarray analyses, Mari Ohnuki for discussion of neural differentiation, Gary Howard and Anna Lisa Lucido for editorial review, Karena Essex for administrative supports, Stem Cell Core for providing stem cell culture services and Bioinformatics Core for conducting the statistic analyses. We also would like to thank Kathrin Plath and Sanjeet Patel for providing their hiPSC lines. K.T. is a scholar of the California Institute for Regenerative Medicine (CIRM). B.P. is funded by NIH R01 GM088506. This work was supported in part by grants from the Leading Project of MEXT (Japan, to SY), the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program) of the JSPS (Japan, to SY), Grants-in-Aid for Scientific Research of the JSPS and MEXT (Japan, to SY), and the Program for Promotion of Fundamental Studies in Health Sciences of NIBIO (Japan, to SY). These studies were also made possible by funding from the Gladstone Institutes, L.K. Whittier Foundation, from NHLBI/NIH (U01-HL100406, U01-HL098179) and the CIRM. The Gladstone Institutes received support from a National Center for Research Resources Grant RR18928-01.

REFERENCES

- Blanchard F, Raheer S, Duplomb L, Vusio P, Pitard V, Taupin JL, Moreau JF, Hoflack B, Minvielle S, Jacques Y, et al. The mannose 6-phosphate/insulin-like growth factor II receptor is a nanomolar affinity receptor for glycosylated human leukemia inhibitory factor. *The Journal of biological chemistry*. 1998; 273:20886–20893. [PubMed: 9694835]
- Brown CJ, Willard HF. The human X-inactivation centre is not required for maintenance of X-chromosome inactivation. *Nature*. 1994; 368:154–156. [PubMed: 8139659]
- Bruck T, Benvenisty N. Meta-analysis of the heterogeneity of X chromosome inactivation in human pluripotent stem cells. *Stem Cell Res*. 2011; 6:187–193. [PubMed: 21276761]
- Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. *Nature*. 2005; 434:400–404. [PubMed: 15772666]
- Cheung AY, Horvath LM, Grafodatskaya D, Pasceri P, Weksberg R, Hotta A, Carrel L, Ellis J. Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. *Hum. Mol. Genet*. 2011; 20:2103–2115. [PubMed: 21372149]
- Fan G, Tran J. X chromosome inactivation in human and mouse pluripotent stem cells. *Hum. Genet*. 2011; 130:217–222. [PubMed: 21678064]
- Hanna J, Cheng AW, Saha K, Kim J, Lengner CJ, Soldner F, Cassady JP, Muffat J, Carey BW, Jaenisch R. Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. *Proc. Natl. Acad. Sci. USA*. 2010; 107:9222–9227. [PubMed: 20442331]
- Heard E, Disteché CM. Dosage compensation in mammals: fine-tuning the expression of the X chromosome. *Genes Dev*. 2006; 20:1848–1867. [PubMed: 16847345]
- Hoffman LM, Hall L, Batten JL, Young H, Pardasani D, Baetge EE, Lawrence J, Carpenter MK. X-inactivation status varies in human embryonic stem cell lines. *Stem Cells*. 2005; 23:1468–1478. [PubMed: 16123389]
- Kim KY, Hysolli E, Park IH. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. *Proc. Natl. Acad. Sci. USA*. 2011; 108:14169–14174. [PubMed: 21807996]
- Lagarkova MA, Shutova MV, Bogomazova AN, Vassina EM, Glazov EA, Zhang P, Rizvanov AA, Chestkov IV, Kiselev SL. Induction of pluripotency in human endothelial cells resets epigenetic profile on genome scale. *Cell Cycle*. 2010; 9:937–946. [PubMed: 20160486]
- Lengner CJ, Gimelbrant AA, Erwin JA, Cheng AW, Guenther MG, Welstead GG, Alagappan R, Frampton GM, Xu P, Muffat J, et al. Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. *Cell*. 2010; 141:872–883. [PubMed: 20471072]
- Lin H, Gupta V, Vermilyea MD, Falciani F, Lee JT, O'Neill LP, Turner BM. Dosage compensation in the mouse balances up-regulation and silencing of X-linked genes. *PLoS biology*. 2007; 5:e326. [PubMed: 18076287]
- Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K, Stadtfeld M, Yachechko R, Tchieu J, Jaenisch R, et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. *Cell Stem Cell*. 2007; 1:55–70. [PubMed: 18371336]

- Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, Chen G, Gage FH, Muotri AR. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. *Cell*. 2010; 143:527–539. [PubMed: 21074045]
- McMahon AP, Bradley A. The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain. *Cell*. 1990; 62:1073–1085. [PubMed: 2205396]
- Mekhoubad S, Bock C, de Boer AS, Kiskinis E, Meissner A, Eggan K. Erosion of Dosage Compensation Impacts Human iPSC Disease Modeling. *Cell Stem Cell*. 2012; 10:595–609. [PubMed: 22560080]
- Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. *Nat. Biotechnol.* 2008; 26:101–106. [PubMed: 18059259]
- Nguyen DK, Distèche CM. Dosage compensation of the active X chromosome in mammals. *Nat. Genet.* 2006; 38:47–53. [PubMed: 16341221]
- Nichols J, Smith A. Naive and primed pluripotent states. *Cell Stem Cell*. 2009; 4:487–492. [PubMed: 19497275]
- Okamoto I, Patrat C, Thepot D, Peynot N, Fauque P, Daniel N, Diabangouaya P, Wolf JP, Renard JP, Duranthon V, et al. Eutherian mammals use diverse strategies to initiate X-chromosome inactivation during development. *Nature*. 2011; 472:370–374. [PubMed: 21471966]
- Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka KI, et al. A more efficient method to generate integration-free human iPSCs. *Nat Methods*. 2011
- Payer B, Lee JT, Namekawa SH. X-inactivation and X-reactivation: epigenetic hallmarks of mammalian reproduction and pluripotent stem cells. *Hum. Genet.* 2011; 130:265–280. [PubMed: 21667284]
- Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, Apostolou E, Stadtfeld M, Li Y, Shioda T, et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. *Nat Biotechnol.* 2010; 28:848–855. [PubMed: 20644536]
- Pomp O, Dreesen O, Leong DF, Meller-Pomp O, Tan TT, Zhou F, Colman A. Unexpected X chromosome skewing during culture and reprogramming of human somatic cells can be alleviated by exogenous telomerase. *Cell Stem Cell*. 2011; 9:156–165. [PubMed: 21816366]
- Shen Y, Matsuno Y, Fouse SD, Rao N, Root S, Xu R, Pellegrini M, Riggs AD, Fan G. X-inactivation in female human embryonic stem cells is in a nonrandom pattern and prone to epigenetic alterations. *Proc. Natl. Acad. Sci. USA*. 2008; 105:4709–4714. [PubMed: 18339804]
- Silva SS, Rowntree RK, Mekhoubad S, Lee JT. X-chromosome inactivation and epigenetic fluidity in human embryonic stem cells. *Proc. Natl. Acad. Sci. USA*. 2008; 105:4820–4825. [PubMed: 18339803]
- Takahashi K, Narita M, Yokura M, Ichisaka T, Yamanaka S. Human induced pluripotent stem cells on autologous feeders. *PLoS One*. 2009; 4:e8067. [PubMed: 19956543]
- Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. 2007; 131:861–872. [PubMed: 18035408]
- Tchieu J, Kuoy E, Chin MH, Trinh H, Patterson M, Sherman SP, Aimiwu O, Lindgren A, Hakimian S, Zack JA, et al. Female human iPSCs retain an inactive X chromosome. *Cell Stem Cell*. 2010; 7:329–342. [PubMed: 20727844]
- Teichroeb JH, Betts DH, Vaziri H. Suppression of the imprinted gene NNAT and X-chromosome gene activation in isogenic human iPSCs. *PLoS One*. 2011; 6:e23436. [PubMed: 22022350]
- van den Berg IM, Laven JS, Stevens M, Jonkers I, Galjaard RJ, Gribnau J, van Doorninck JH. X chromosome inactivation is initiated in human preimplantation embryos. *Am. J. Hum. Genet.* 2009; 84:771–779. [PubMed: 19481196]
- Ware CB, Wang L, Mecham BH, Shen L, Nelson AM, Bar M, Lamba DA, Dauphin DS, Buckingham B, Askari B, et al. Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. *Cell Stem Cell*. 2009; 4:359–369. [PubMed: 19341625]

Highlights

- X-Inactivation status in female hiPSC lines depends on derivation conditions.
- hiPSC lines generated by the Kyoto method on SNL feeders frequently had two Xas.
- Leukemia inhibitory factor (LIF) is a key factor in X activation.
- Xa/Xa hiPSC lines are valuable tools for understanding human X- inactivation.




Figure 1. X-Linked Genes Are Highly Expressed in Female hiPSC Lines

(A and D) Experimental design to generate hiPSC lines from H9 ESCs (A) and from hFibs (D). The X-inactivation status of the each cell line is also shown. The characterizations of the hiPSC lines are shown in Figure S1 and Table S1.

(B and E) Heat maps of relative expression levels of the X-linked genes. All cell lines were cultured in identical conditions. RNA was extracted from H9r iPSC lines at p3 and female hiPSC lines from hFibs at >p15.

(C) Percentage of all X-linked genes (probes) that are up-regulated (red) or down-regulated (green) by more than 1.5-fold in the H9r iPSC lines and female (Xa/Xi) hESC lines (average data among ESI03, H9-reporter and H9) or the male (XY) ES H1 cell line.

(F) Gene expression ratios on the genome. The expression ratios between female hESC (average data among ESI03, H7, H9 and H9-reporter) and hiPSC (average data among K-3F-1, K-3F-2 and 3S-5F-4) lines are plotted on human genome. Blue bars indicate where each gene maps. Blue bars above the red midline show highly expressed genes in the hESC lines. Blue bars below the midline show highly expressed genes in the hiPSC lines. The height of bars indicates the expression ratio of each gene. Chromosome numbers are shown on top of the diagram. The Y chromosome is excluded in this assay. The X chromosome is expanded in the inset.




Figure 2. Two Xs Are Active in Female hiPSCs

(A) RNA FISH for *PGK1* (green) and *XIST* (red) in hESCs and hiPSCs derived on SNLs.

(B) Graph showing the proportion of cells with 0, 1, or 2 sites of *PGK1* nascent mRNA accumulation in Xa/Xi hESC (ESI03) and two female hiPSC (K-3F-2 and 3S-5F-4) lines.

(C) Relative expression levels of *XIST*. The expression levels of *XIST* were extracted from microarray data sets. The male ESC line H1 is used for normalization. Female fibroblasts (hFib) from which the hiPSC lines were generated and Xa/Xi hESCs (ESI03) served as controls.

(D) Immuno-FISH. Representative images for localization of RNA polymerase II (RNA polII) (green) and X chromosomes (red) in the indicated cell lines. Arrows show regions depleted of staining for RNA polII in which one of two X chromosomes localizes. The percentage of cells in which no RNA polII exclusion from an X was observed is inset.

(E) *WDR44* expression in the indicated cell lines was determined by RT-qPCR (left graph). The expression values in the H9-reporter and expression levels of *GAPDH* were used for normalization. Error bars are standard deviations. The right bar graph shows the percentage of clones that contain T or C at the same position in *WDR44* RNA in the indicated cell lines. Five H9-reporter and six H9r-3F-2 clones were sequenced.

(F) Methylation patterns of the *WDR44* promoter in the indicated cell lines. Each circle denotes a CpG sequence in the promoter region. Black circles, methylated CpGs; white circles, unmethylated CpGs; gray circles, mutated CpGs. Each row for each cell line shows each sequenced clone for the cell lines.

(G) Each dot shows the expression ratio between X-linked genes and autosomal genes from each cell line. In left three lanes, deposited microarray data sets for cell lines in which X-inactivation status was already examined are used, and the X/A ratios are plotted as controls. The remaining lanes show X/A ratios from the same lines used in Figure 1. The X/A ratios are also shown in Table S1.

(H) X/A ratios from undifferentiated (Undiff) and differentiated (Diff) hESCs and hiPSCs, (each color dot represents a single cell line before and after differentiation) and primary

human endothelial cells from biopsy (Primary; red, purple = female, green = male). The X/A ratios from the undifferentiated hESCs and hiPSCs were also used in Figure 1G.

(I) RNA FISH for *XIST* (red) and *PGK1* (green) in endothelial cells differentiated from indicated Xa/Xa hiPSC lines. Undifferentiated Xa/Xi hESC line ESI03 and Xa/Xa hiPSC line K-3F-2 serve as controls.

(J) Graph showing the proportion of cells exhibiting 0, 1 or 2 sites of nascent PGK1 mRNA accumulation in undifferentiated (K-3F-2; left) and differentiated (K-3F-2 and 3S-5F-4) hiPSCs. 5–15% of differentiated cells exhibit tetraploidy, similar to the proportion of these cells that exhibit two sites of PGK1 RNA accumulation.




Figure 3. Prolonged Culture Promotes X-Reactivation when Propagated on SNL Feeders
 (A) X/A ratios from hFib-derived female hiPSC lines at p5 or > p15. Cell lines were generated on SNLs or on non-SNLs. X/A ratios from hiPSC lines in which X-inactivation status was further examined in Figure 3 by FISH and/or SNP sequencing are shown in green, including three cell lines used in Figures 1 and 2. Those examined in Figure 4 are shown in orange. X/A ratios from deposited Xa/Xi and Xa/Xa cell lines are shown in red. Cell lines above the upper black line in the graph have a predicted probability of at least 0.95 of being Xa/Xa, while those below the lower black line have a predicted probability of at least 0.95 of being Xa/Xi or a 0.05 probability of being Xa/Xa (see more details in Figure S2 and EXTENDED EXPERIMENTAL PROCEDURES). The X/A ratios are also shown in Table S1.

(B) Graph showing the proportion of cells exhibiting 0, 1 or 2 sites of nascent PGK1 mRNA accumulation in Xa/Xi hESC (ESI03) and three hiPSC lines (K-3F-2, 201B7 and 923S3) on SNLs at > p15. X/A ratios from indicated lines are also shown.

(C) Relative expression levels of *XIST* and *NANOG*. RNA from the three hiPSC lines (K-3F-1, K-3F-2 and 3S-5F-4) was extracted at indicated passage number and analyzed by RT-qPCR. *NANOG* was used as a pluripotency marker. The Xa/Xi hESC line (ESI03) and female fibroblasts (hFib) from which the hiPSCs were generated served as controls. The y-axis is in logarithmic scale. Expression values of *XIST* in 3S-5F-4 at p24 and of *NANOG* in hFib were set as 1.0.

(D) SNP sequencing of two X-linked genes (*TSPAN6* and *FRMPD4*) in one hiPSC line K-3F-2 on SNLs at p3 and p24. Arrows show position of SNPs.

(E) RNA FISH for *PGK1* (green) and *XIST* (red) in hiPSCs derived on hFibs. The hiPSC line 297C1 contains a mixed population of cells that do and do not express *XIST*.

(F) Graph showing the proportion of cells with 0, 1, or 2 sites of *PGK1* nascent mRNA accumulation in three hiPSC lines generated and cultured on non-SNLs at > p12. X/A ratios are included beneath the graph.




Figure 4. SNLs Have a Role in X-Reactivation in Female hiPSCs

(A) Diagram outlining experimental design. Related experiments are also shown in Figure S3.

(B and C) X/A ratios of hiPSC lines generated on non-SNLs and cultured as in Figure 4A. “Before” indicates ratios at p9 (B) and p3 (C), and “After” indicates at >p15 under the conditions indicated in Figure 4A. According to our model, cell lines above the upper black line in the graph have a 0.95 probability of being Xa/Xa, those below the lower black line have a 0.95 probability of being Xa/Xi.

(D and F) Normalized *XIST* expression in hiPSCs before and after transfer to SNLs (D) or before and after transfer to rLIF (F).

(E and H) SNP sequencing for *FRMPD4* and *TSPAN6* in hiPSCs before (p5) and after transfer to SNLs (p15) (E) or p15 hiPSCs on MEFs or MEFs plus rLIF (H). The hiPSC line 923M3 exhibits some bi-allelic expression of both genes at p5 on MEFs, consistent with both genes escaping X-inactivation at low frequency (Carrel and Willard, 2005).

(G) Graph showing the proportion of cells with 0, 1, or 2 sites of *PGK1* nascent mRNA accumulation in indicated conditions.

(I) X-Linked gene expression ratios plotted on the X. The probe locations are shown under the X diagram (note that many regions of the X do not have probes). The ratios of SNL hiPSCs and MEF hiPSCs (top bar chart) or between MEF plus rLIF hiPSCs and MEF hiPSCs (bottom bar chart) in hiPSC 923M2 are shown as bar charts. Each blue bar shows ratios for each gene analyzed. Blue bars above the orange line show up-regulated genes in SNL hiPSCs or MEF plus rLIF hiPSCs compared with MEF hiPSCs, and below the orange line show down-regulated genes. Line labeled (a) indicates a region of the X where gene expression on MEFs and MEFs plus rLIF is comparable, (b) indicates a region where genes are up-regulated to a similar extent on SNLs and MEFs plus rLIF, and (c) indicates a region where genes are up-regulated to a lesser degree on MEFs plus rLIF than on SNLs. Location of *FRMPD4* is indicated with an arrowhead.